Surgical Salvage Improves Survival in Metastatic Oropharyngeal Cancer

Share this content:

the Cancer Therapy Advisor take:

Improved overall survival (OS) was found to be associated with surgical salvage in patients with recurrent locoregional and distant metastatic oropharyngeal squamous cell carcinoma (OPSCC), independent of human papillomavirus (HPV) tumor status, according to an article published online in the journal Cancer.

Participants in the study included patients with recurrent OPSCC from two institutions from 2000 to 2012.  Immunohistochemistry and/or in situ hybridization were used to evaluate the status of each patient’s tumor.  Kaplan-Meier and Cox proportional hazards methods were used to evaluate OS.

The majority of patients (80 out of 108) were HPV-positive, 65 of the patients had locoregional metastatic first recurrences and 43 had distant metastatic first recurrences.  HPV-positive tumor status was found to be related to a longer time to disease recurrence (P<0.01). Several factors have an independent association with OS after disease recurrence: HPV-positive tumor status (aHR = 0.23; 95% CI: 0.09, 0.58;P=0.002), longer time to disease recurrence (≥1 year; aHR = 0.36; 95% CI: 0.18, 0.74; P=0.006), and surgical salvage (aHR = 0.26; 95% CI: 0.12, 0.61; P=0.002). Furthermore, researchers found an independent association between surgical salvage and improved OS compared with nonsurgical treatment among patients with both locoregional (aHR = 0.15; 95% CI: 0.04, 0.56; P=0.005) and distant (aHR = 0.19; 95% CI: 0.05, 0.75; P=0.018) metastatic disease recurrences.

The study suggests that further data be obtained to confirm the impact of surgical salvage on OS among patients with distant metastases. 

No Benefits from Neoadjuvant Gemcitabine + Carboplatin + Paclitaxel in Nasopharyngeal Cancer
Improved overall survival found to be associated with surgical salvage in metastatic oropharyngeal squamous cell carcinoma.

Surgical salvage was found to be associated with improved OS for patients with recurrent locoregional and distant metastatic OPSCC, independent of HPV tumor status.

READ FULL ARTICLE From Wiley Online Library

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs